Payment overview · 2025
General Payments
$146.17
9 reported records · 7 companies
Healthcare provider profile · identity verified
Aurora C. Bell, DO
Allopathic & Osteopathic Physicians|Family Medicine · LANCASTER, MO · NPI 1598116196
Verified facts
What the public records show
CMS Open Payments records show Aurora C. Bell, DO received $146.17 in general payments during 2025 across 9 reported records.
Novartis Pharmaceuticals Corporation accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.98 | 21.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.29 | 20.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.28 | 19.4% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.55 | 13.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.94 | 12.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.14 | 9.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.99 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.17 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 54 |
| Lisinopril | Lisinopril | 253 | 46 |
| Gabapentin | Gabapentin | 242 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 37 |
| Metformin Hcl | Metformin Hcl | 170 | 26 |
| Eliquis | Apixaban | 166 | 14 |
| Potassium Chloride | Potassium Chloride | 165 | 25 |
| Furosemide | Furosemide | 158 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 23 |
| Sertraline Hcl | Sertraline Hcl | 135 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 14 |
| Jardiance | Empagliflozin | 103 | suppressed |
| Losartan Potassium | Losartan Potassium | 98 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 15 |
| Xarelto | Rivaroxaban | 90 | suppressed |
| Omeprazole | Omeprazole | 87 | 16 |
| Tramadol Hcl | Tramadol Hcl | 86 | 30 |
| Famotidine | Famotidine | 84 | 14 |
| Simvastatin | Simvastatin | 84 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 16 |
| Donepezil Hcl | Donepezil Hcl | 78 | suppressed |
| Carvedilol | Carvedilol | 74 | 18 |
| Montelukast Sodium | Montelukast Sodium | 70 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 14 |
| Prednisone | Prednisone | 66 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 18 |
| Lorazepam | Lorazepam | 58 | 14 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Cephalexin | Cephalexin | 57 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 11 |
| Fluconazole | Fluconazole | 54 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 51 | 11 |
| Rexulti | Brexpiprazole | 50 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 47 | suppressed |
| Torsemide | Torsemide | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 11 |
| Trazodone Hcl | Trazodone Hcl | 44 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | suppressed |
| Baclofen | Baclofen | 41 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 16 |
| Linzess | Linaclotide | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 19 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Ozempic | Semaglutide | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 28 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 13 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Xcopri | Cenobamate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Hetlioz | Tasimelteon | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Mupirocin | Mupirocin | 14 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tasimelteon | Tasimelteon | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.17 · 9 records | Novartis Pharmaceuticals Corporation | AREXVY, AUSTEDO XR, BREZTRI, CAPLYTA, LEQVIO, PENMENVY, Quviviq, SHINGRIX, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error